#China #Suzhou #Ribocure Pharmaceuticals #SR122 #Suzhou Ribo Life Science

Ribo Launches Clinical Trial for SR122

Suzhou Ribo Life Science, in conjunction with its subsidiary Ribocure Pharmaceuticals AB, has officially submitted a Phase I clinical trial application for its innovative small interfering RNA (siRNA) drug, SR122, targeting severe dyslipidemia in Europe. This submission marks a significant advancement in their strategy to combat lipid disorders, particularly concerning conditions like severe hypertriglyceridemia (sHTG) and mixed dyslipidemia.

Understanding SR122

SR122 stands out in its design as an RNA interference based therapy conjugated with GalNAc, a technology aimed at improving the efficacy and specificity of treatment. By engaging two validated clinical pathways—ApoC3 and PCSK9—this dual-targeting approach is anticipated to deliver synergistic effects on lipid metabolism. The drug aims to address not just triglyceride-rich lipoproteins but also low-density lipoprotein cholesterol (LDL-C), thereby presenting a multi-faceted therapeutic avenue for patients affected by challenging lipid profiles.

The Clinical Context of Dyslipidemia

Dyslipidemia remains a global health challenge, exacerbating the risk of cardiovascular diseases, which are currently the leading cause of mortality worldwide. For patients suffering from mixed dyslipidemia, existing lipidemic therapies often leave residual cardiovascular risks, compelling the need for innovative treatment alternatives like SR122. Severe hypertriglyceridemia presents even greater threats, including a heightened risk of acute pancreatitis, underscoring the critical need for effective interventions.

Phase 1 Trial Design

The Phase I clinical study is a randomized, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SR122 through subcutaneous administration in healthy participants. This study will provide invaluable insights into the human clinical response to SR122's dual-targeting mechanism and is expected to confer foundational data for further developmental stages in targeted populations.

Dr. Anders Gabrielsen, CMO of Ribo, expressed optimism regarding the therapeutic potential of SR122, stating, "The simultaneous suppression of ApoC3 and PCSK9 presents a superior synergy to mitigate extreme lipid risk in cases of severe hypertriglyceridemia, paving the way for more comprehensive risk management in affected patients. The results from the Phase I trial will guide subsequent clinical development in the intended target population."

Future Directions

As Ribo progresses with SR122, it concurrently moves forward with Phase II studies involving its primary lipid asset, RBD5044, which is the second most advanced siRNA targeting ApoC3 globally. The successful development and clinical validation of SR122 reinforce Ribo's commitment to leading innovation in the management of lipid disorders.

This ambitious undertaking not only positions Ribo at the forefront of biotechnology advancements in lipid therapies but also aims to significantly impact the clinical landscape for patients grappling with complex dyslipidemic conditions, ultimately aiming to improve long-term cardiovascular health outcomes.